Main Category: Stem Cell Research
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 05 Sep 2013 – 2:00 PDT
Histogen. “Histogen’s method of generating multipotent stem cells receives US patent.” Medical News Today. MediLexicon, Intl., 5 Sep. 2013. Web.
5 Sep. 2013. <http://www.medicalnewstoday.com/releases/265684.php>
MLA
Contact Our News Editors
“Histogen’s process is uniquely capable of harnessing all of the benefits and excitement of stem cell therapies without any of the ethical, safety or sourcing concerns,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “Issuance of this patent adds great strength to our technology, and value to our partners and products.”
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Histogen, Inc., a regenerative medicine company developing innovative therapies for conditions including hair loss and cancer, has announced that the United States Patent & Trademark Office has issued patent 8,524,494, entitled “Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro” to the Company.
It is the soluble and insoluble compositions of multipotent proteins and growth factors which make up Histogen’s products, with numerous applications. Histogen’s lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen’s process can be found in the ReGenica line of skincare products, currently being distributed by Suneva Medical in partnership with Obagi Medical Products. Further indications of the materials currently being developed include oncology and orthopedics.
stem cell research section for the latest news on this subject.